Evaxion Biotech A/S Adr ((EVAX)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evaxion Biotech’s latest earnings call struck a notably upbeat tone, driven by strong scientific momentum across its AI-Immunology platform and lead cancer vaccine EVX-01. Management highlighted robust immunogenicity data, encouraging clinical responses and growing validation in hard-to-treat tumors, while acknowledging ongoing funding needs and the absence of finalized partnerships.
EVX-01 Shows Robust Immunogenicity in Phase II
Phase II translational data for EVX-01 showed an 86% immunogenicity conversion rate and an 86% de novo T-cell response rate, pointing to broad and novel T-cell activation in patients. Management underscored a positive correlation between predicted vaccine-target quality and response magnitude, strengthening confidence in the predictive power of the company’s AI-Immunology engine.
Clinical Outcomes Underscore EVX-01’s Potential
The call revisited prior clinical data where EVX-01 achieved a 75% overall response rate, with more than half of patients improving their clinical response and durable benefit signals highlighted by 25 complete responders. EVX-01 has secured FDA Fast Track status, and Evaxion plans a three-year outcome update in the second half of 2026 to further clarify durability and survival benefits.
AI Platform Extends to Glioblastoma and Low-Mutation Tumors
In collaboration with Duke University, Evaxion’s platform produced fully personalized vaccine designs for all 24 evaluated glioblastoma patients, underlining technical feasibility. Notably, 21 of 24 designs combined classical neoantigens with endogenous retrovirus antigens, suggesting the approach could address low mutational burden tumors and push the platform beyond its melanoma roots.
Reinventing Polio Vaccines with Global Partners
Evaxion also showcased its collaboration with The Gates Foundation, using AI-Immunology to design a hybrid capsid antigen and a de novo B-cell antigen for an improved polio vaccine concept. Management argued that this work illustrates the platform’s ability to modernize classical vaccines, targeting broader immune coverage and potentially simpler vaccine formulations.
Clinical and Preclinical Validation Across Multiple Diseases
The company framed its AI-Immunology platform as clinically validated, citing positive outcomes in all three oncology trials referenced to date. Beyond oncology, management pointed to preclinical proof-of-concept in infectious disease and autoimmune settings, emphasizing support for multiple modalities from peptides and proteins to DNA and RNA, and positioning the platform for diverse partnership structures.
Organizational Moves to Align Science and Strategy
On the corporate side, Evaxion promoted Birgitte Rono to a combined CSO and COO role, aiming to closely align scientific direction with operational execution. The appointment of Jens Bitsch-Norhave to the Board was presented as strengthening business development and strategic capabilities, signaling a more outward-facing posture toward potential partners.
Disciplined Cost Control and Runway to H2 2027
Management reiterated a focus on disciplined spending, guiding to an operating cash burn of around USD 14 million in 2026 and noting Q1 operating expenses were broadly flat year over year. With USD 18.4 million in cash and equivalents at quarter-end, Evaxion expects to fund operations into the second half of 2027 based on current plans and without assuming any new deals.
Active but Unclosed Business Development Pipeline
The company reported multiple ongoing partnering discussions across oncology and infectious disease assets, describing business development as a key strategic priority. Management indicated that certain programs, such as glioblastoma, are explicitly being steered toward partnership structures, though no definitive agreements or timelines were disclosed during the call.
Runway Limits Highlight Funding and Dilution Risk
Despite the extended runway, Evaxion acknowledged that its USD 18.4 million in cash and roughly USD 14 million planned burn for 2026 leave it reliant on future partnerships or financings beyond H2 2027. Investors were reminded that runway projections exclude potential deals, underscoring a finite funding horizon and the ongoing need to secure external capital.
Ongoing Losses and Eroding Equity Base
Evaxion posted a Q1 net loss of USD 3.6 million, consistent with its profile as a clinical-stage biotech investing heavily in R&D. Total equity declined to USD 13.2 million at quarter-end, reflecting continued capital consumption and highlighting the importance of future fundraising or partnership-derived cash inflows.
Promising Programs Still Need Data and Partners
Management stressed that emerging indications such as glioblastoma and autoimmune diseases, while scientifically encouraging, remain at an early stage and will require further development. These programs are expected to progress via partnerships, with additional autoimmune updates and key translational data targeted for the second half of 2026, making execution on collaborations a critical milestone.
Guidance Emphasizes Focused Spend and Key Milestones
Looking ahead, Evaxion guided to an operating cash burn of about USD 14 million in 2026, with R&D modestly higher and G&A slightly lower, maintaining cash runway into H2 2027. On the pipeline side, the company highlighted completed last-patient visits in the EVX-01 Phase II extension, three-year outcome data expected in H2 2026, EVX-04 targeted for clinical readiness by year-end 2026 and continued efforts to validate and monetize its AI-Immunology platform through partnerships.
Evaxion’s earnings call painted a picture of a platform-rich biotech advancing compelling cancer and vaccine assets while walking a familiar tightrope of funding constraints. Strong immunogenicity and response data for EVX-01, expanding applications in glioblastoma and novel vaccine designs support the long-term story, but investors will be watching closely for concrete partnerships and capital solutions over the next several quarters.